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Cytokine gene polymorphisms are 
not associated with anti-PvDBP, anti-PvAMA-1 
or anti-PvMSP-119 IgG antibody levels in a 
malaria-endemic area of the Brazilian Amazon
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Abstract 
Background: The immune response against Plasmodium vivax immunogenic epitopes is regulated by pro‑ and 
anti‑inflammatory cytokines that determine antibody levels and class switching. Cytokine gene polymorphisms may 
be responsible for changes in the humoral immune response against malaria. The aim of this study was to evaluate 
whether polymorphisms in the TNFA, IFNG and IL10 genes would alter the levels of anti‑PvAMA1, PvDBP and ‑PvMSP‑
119 IgG antibodies in patients with vivax malaria.
Methods: Samples from 90 vivax malaria‑infected and 51 uninfected subjects from an endemic area of the Brazilian 
Amazon were genotyped using polymerase chain reaction‑restriction fragment length polymorphism (PCR–RFLP) 
to identify polymorphisms of the genes TNFA (−1031T > C, −308G > A, −238G > A), IFNG (+874T > A) and IL10 
(−819C > T, −592C > A). The levels of total IgG against PvAMA1, PvDBP and PvMSP‑119 were determined using an 
enzyme‑linked immunosorbent assay (ELISA). Associations between the polymorphisms and the antibody response 
were assessed by means of logistic regression models.
Results: No significant differences were found in the levels of IgG antibodies against the PvAMA‑1, PvDBP or PvMSP‑
119 proteins in relation to the studied polymorphisms.
Conclusions: Although no associations were found among the evaluated genotypes and alleles and anti‑merozoite 
IgG class P. vivax antibody levels, this study helps elucidate the immunogenic profile involved in the humoral immune 
response in malaria.
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Background
Early diagnosis, prompt and effective treatment, the use 
of mosquito nets impregnated with long-acting insec-
ticides and residual intradomiciliary spraying are the 
main malaria control measures [1] and have resulted in 
a reduction in the transmission and number of cases of 
malaria in Brazil. However, this disease remains one of 
the most prevalent infections in tropical countries, with 
214 million clinical cases/year and approximately 438,000 
deaths [2]. In Brazil, Plasmodium vivax is the aetiologic 
agent in 85 % of cases, and 99.9 % of cases occur in the 
Brazilian Amazon region [2].
The different clinical manifestation patterns of malaria 
may be related to host and agent genetic factors, age and 
ethnicity as well as the involvement of these factors in the 
immune response and parasitaemia and antibody levels 
[3–5]. IgG antibodies play a protective role against para-
site invasion in the erythrocytic cycle of Plasmodium [3, 6]. 
For Plasmodium knowlesi, anti-PvAMA-1 monoclonal 
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antibodies have been shown to be capable of inhibit-
ing merozoite invasion in  vitro [7]. PvDBP antibodies 
inhibit interactions with the Duffy antigen receptor for 
chemokines (DARC) in erythrocytes [8], and antibodies 
produced against PvMSP-119 have been shown to prevent 
merozoite invasion in vitro [9]. The synthesis of immuno-
globulins is complex and depends on the process of antigen 
presentation by B lymphocytes (BL) to TCD4 lymphocytes 
and the involvement of co-stimulatory molecules and their 
receptors [10].
The production, levels and switching of antibody 
classes is regulated by pro- and anti-inflammatory 
cytokines [3, 6, 11, 12]. IFN-γ can negatively modulate 
the humoral immune response, thus interfering with cir-
culating antibody levels [13] and increasing IgG2 produc-
tion. TNF appears to be important in the development 
of the humoral response as an autocrine growth factor 
for B cells [6]. Among the anti-inflammatory cytokines, 
IL-10 may participate in negative immunomodulation of 
the Th1-type response [14, 15] in addition to inducing 
immunoglobulin synthesis [6].
Many genetic variants are responsible for minor 
changes in the immune response in malaria [11, 12]. Pre-
vious studies in Brazil with vivax malaria have evaluated 
factors associated with genetic variability in the humoral 
immune response. HLA-DR16 is associated with the IgG 
antibody response to the P. vivax VK247 variant circum-
sporozoite protein [16]. High levels of MSP-1 antibodies 
are also associated with HLA-DR3 [17]. In Goianésia do 
Pará, a municipality located in the Brazilian Amazon, two 
studies evaluated the effects of polymorphisms in genes 
involved in the humoral immune response. Cassiano et al. 
[10] found that the frequency of specific IgG responders 
against PvAMA-1, PvDBP and PvMSP-119 was associated 
with polymorphisms in the BLYS (−871C  >  T), CD40 
(−1C > T) and CD86 (+1057G > A) genes. In contrast, 
genotypes and haplotypes of the IL4 gene were not asso-
ciated with the production of PvAMA-1 antibodies [18]. 
The aim of this work was to continue the search for the 
genetic basis of these traits and to evaluate whether poly-
morphisms in the TNFA, IFNG and IL10 genes alter the 
levels of anti-PvAMA1, -PvDBP and -PvMSP-119 IgG 
antibodies.
Methods
Study area and subjects
Ninety samples from vivax malaria-infected subjects and 
51 samples from uninfected subjects were collected in 
Goianésia do Pará (03°50′33″S; 49°05′49″ W). The sub-
jects were in a sub-group of individuals previously ana-
lysed by Cassiano et al. [10]. The study has evaluated the 
effect of genetic ancestry on the distribution of polymor-
phisms in the TNFA, IFNG and IL10 genes (unpublished 
data). No differences were observed in the mean propor-
tion of any ancestry among the different genotypes and 
haplotypes analysed.
In 2011 and 2012, the numbers of malaria cases were 
2856 and 1136, respectively, with 79 % of cases caused by 
P. vivax. Samples were collected at the municipal health 
center between February 2011 and August 2012. Data 
were collected by passive detection in Basic Health Units 
after thick blood film phenotypic diagnosis, but prior 
to treatment. All patients if malaria were given stand-
ard treatment of 1500 mg of chloroquine in 3 days (600, 
450 and 450  mg) plus 30  mg of primaquine on the day 
the diagnosis and on the following 6  days. Individuals 
infected with P. vivax presented for medical care because 
of clinical symptoms of malaria and they were recruited 
after diagnosis. The uninfected individuals who sought 
medical care offered during the study were invited to par-
ticipate in the study. These individuals experienced the 
same conditions of exposure to the aetiological agent. 
All participants or guardians signed the consent form, 
and the project was approved by the Goianésia do Pará 
health authorities and by the Research Ethics Committee 
(CAAE 01774812.2.0000.5415) of the College of Medi-
cine of São José do Rio Preto (Faculdade de Medicina de 
São José do Rio Preto).
Malaria was diagnosed using thick blood smears 
stained with Giemsa and subsequently confirmed by 
nested-PCR with modifications [19]. No uninfected indi-
vidual was positive in nested-PCR, while five individuals 
positive for P. vivax (thick blood smear) had mixed infec-
tion with Plasmodium falciparum (by nested-PCR) and 
were excluded from the study. Parasitaemia was defined 
as the number of parasites per microlitre of blood after 
examination of 100 microscopic fields.
Peripheral blood was stored at −20  °C. The examina-
tion of polymorphisms in the genes TNFA, IFNG and 
IL10 was performed via PCR amplification followed by 
restriction fragment length polymorphism (RFLP) analy-
sis or the amplification of specific alleles (Table 1).
The amplified products were subjected to electro-
phoresis (100  V/50  min) in 1.5 to 2.5  % agarose gels 
stained with Gel Red (Biotium, CA, USA) or in eth-
idium bromide-stained 12.5  % polyacrylamide gels 
(10 mg/ml) and were visualized using a transilluminator 
(Biotecnologia-Locus).
Assessment of the serological response 
against Plasmodium vivax
The levels of IgG class anti-MSP-119, anti-PvAMA-1 and 
anti-PvDBP antibodies in a larger cohort were previously 
reported by Cassiano et  al. [10]. The analyses were per-
formed using ELISA following previously described pro-
tocols [24–26]. A recombinant protein (His6-MSP-119) 
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comprising amino acids 1616–1704 of MSP-119 [24] and 
domain II of the DBP protein [25] of P. vivax (SAll strain) 
was expressed in Escherichia coli. A protein ectodomain 
(amino acids 43–487) expressed in Pichia pastoris was 
used for PvAMA-1 [26]. The reactivity index (RI) was cal-
culated to define samples as reactive or non-reactive and 
was determined by dividing the sample OD value by the 
cut-off point. Samples with RI ≥ 1 were considered posi-
tive, and those with RI < 1 were considered negative. The 
cut-off point was established as the mean OD (plus three 
standard deviations) of the 40 plasma samples collected 
from subjects with no history of malaria who were living 
in São José do Rio Preto, which is located in the interior 
of the state of São Paulo (a non-malaria-endemic area). 
The control samples were only used for the determina-
tion of serological response.
Statistical analysis
Statistical analysis was performed using R software v 
2.11.1. The genotypic and allelic frequencies of each 
variant were calculated using the genetics package [27]. 
This package was used to evaluate Hardy–Weinberg 
equilibrium deviations using the Chi square test and the 
linkage disequilibrium between locus pairs was calculated 
using the D′ parameter. Haplotypes frequencies were 
estimated using the maximum likelihood method with 
the EM (expectation–maximization) algorithm, which is 
part of the haplo stats package [28]. Differences between 
the proportions of responders and non-responders were 
evaluated using the Chi square test. A non-parametric 
Kruskal–Wallis test was used to identify differences in 
antibody levels and genotypes. P values less than 0.05 
were considered significant.
Results
The genotypic frequencies of the six examined single 
nucleotide polymorphisms (SNPs) are summarized in 
Table  2. The allelic frequencies of the evaluated SNPs 
were in Hardy–Weinberg equilibrium. For the IFNG 
gene, allele A was the most frequent, with 67.3  % at 
position +874T  >  A. For positions −592C  >  A and 
−819C > T of the IL10 gene, the C allele was most com-
mon, with frequencies of 68.8 and 65.6  %, respectively. 
Finally, for the TNFA gene at positions −238G  >  A, 
Table 1 Polymorphisms, methods, restriction enzymes, primers, and  band patterns used for  investigation of  SNPs 
in genes TNFA, IFNG, IL10
Polymorphisms 
in gene
SNP Method enzimas 
annealing
Primers Genotype Reference
IFN γ −183
G > T
rs2069709 RFLP (53º)
Eco47I
FW: 5′‑AAT GAT CAA TGT GCT TTG 
TG‑3′
R: 5′‑TAA GAT GAG ATG GTG ACAG‑3′
TT: 271 pb
GT: 271 pb, 164 pb, 107pb
GG: 164pb, 107 pb
Suxia Qi et al. [20]
IFN γ +874
A > T
rs2430561 ASO‑PCR (53º) CP: ‑5′‑TCA ACA AAG CTG ATA CTC 
CA‑3′
T : 5′‑TTC TTA CAA CAC AAA ATC AAA 
TCT‑3′
A: 5′‑TTC TTA CAA CAC AAA ATC AAA 
TCA‑3′
AA: 262 pb (reação A)
TT: 262 pb (reação T)
AT: 262 pb (reação A, T)
Medina et al. [21]
TNF α −238
G > A
rs 361525 RFLP (60º)
MspI
FW: 5′‑ATC TGG AGG AAG CGG TAG 
TG‑3′
R: 5‑AGA AGA CCC CCC TCG GAA 
CC’ 3′
AA: 156 pb
GG: 133 pb
GA: 153 pb, 133 pb
Hedayati et al. [22]
TNFα −308
G > A
rs 1800629 RFLP (59º)
NcoI
FW: 5′‑GAG GCA ATA GGT TTT GAG 
GGC CAT‑3′
R: 5′‑GGG ACA CAC AAG CAT CAAG 3′
AA: 147 pb
GG: 126 pb, 121 pb
GA: 147 pb, 126 pb, 21 pb
Asghar et al. [23]
TNFα −1031
T > C
rs1799964 RFLP (57º)
BbsI
FW: 5′‑TAT GTG ATG GAC TCA CCA 
GGT‑3′
R: 5′‑CCT CTA CAT GGC CCT GTC TT 3′
TT: 251 pb, 13 pb
TC: 251 pb, 180 pb, 71 pb 
e 13 pb
CC: 180 pb, 71 pb e 13 pb
Asghar et al. [23]
IL‑10 −592
C > A
rs1800872 RFLP (54º)
RsaI
FW: 5′‑GGG TGA GGA AAC CAA ATT 
CTC‑3′
R:5′‑GAG GGG GTG GGC TAA ATA TC 3′
AA: 240 pb, 77 pb, 36 pb e 
08 pb
CC: 317 pb,36 pb e 08 pb
CA: 317 pb, 240 pb, 77 pb, 
36 pb e 08 pb
IL‑10 −819
C > T
rs1800871 RFLP (54º)
RseI
FW: 5′‑GGG TGA GGA AAC CAA ATT 
CTC‑3′
R: 5′‑GAG GGG GTG GGC TAA ATA 
TC 3′
TT: 270 pb e 91 pb
CC: 217 pb, 91 pb e 53 pb
TC: 270 pb, 217 pb, 91 pb 
e 53 pb
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−308G  >  A and −1031T  >  C, the most frequent alleles 
were G (94.32 %), G (86.17 %) and T (75.18 %).
Antibodies levels (PvAMA-1, PvDBP or PvMSP-119) 
were significantly higher in individuals with malaria than 
in uninfected (Additional file  1). No significant differ-
ences were found in the levels of IgG antibodies against 
the PvAMA-1, PvDBP or PvMSP-119 proteins in relation 
to the studied polymorphisms (Table 2, P > 0.05, Kruskal–
Wallis test). It was possible to genotype some samples 
of patients with malaria to the IFNG (+874A > T) gene 
rs2430561. This result did not change in the regression 
analyses after adjusting for covariates affecting anti-
body levels (current infection status, previous history of 
malaria and gender). The logistic regression analyses also 
revealed no significant differences between haplotypes in 
relation to antibody levels (Table 3).
Discussion
Cytokines such as TNF, IFN-γ and IL-10 participate in 
cellular and humoral immune modulation in malaria 
and affect pathogenesis, parasitaemia control and patho-
physiology, which are dependent on the cellular and 
circulating levels of these cytokines [3, 21, 29, 30]. It is 
hypothesized that polymorphisms in the genes encoding 
these cytokines could be found in genetic markers and 
would affect the levels of IgG anti-merozoite antibodies 
in individuals with vivax malaria. Limited data are avail-
able in the literature, and studies examining associations 
between antibodies and SNPs in cytokine genes in gen-
eral have been conducted only for P. falciparum. The aim 
of the present study was to evaluate the importance of 
polymorphisms in the genes TNFA, IFNG and IL10 in the 
antibody response of P. vivax vaccine candidate proteins. 
However, analysis identified no significant association.
IFN-γ is a key pro-inflammatory cytokine for the 
induction of essential immune effector mechanisms in 
initial infection control in both the hepatic and erythro-
cytic phases of malaria [31, 32]. The production of this 
cytokine is related to low parasitaemia in the acute phase; 
however, a balance with anti-inflammatory cytokines, 
such as IL-10 and TGF-beta, is necessary to reduce severe 
forms of malaria [32]. The SNP at position +874 T > A 
affects an NFkB pathway that determines the production 
of inflammatory cytokines [33, 34]. An association has 
Table 2 Levels of IgG antibodies against P. vivax blood stage proteins according to the studied genotypes
Values are presented as medians (IQ)
Gene SNP PvAMA-1  
(n = 135)
P value PvDBP  
(n = 135)
P value PvMSP-119
(n = 128)
P value
INFG +874T > A 0.19 0.40 0.42
AA 1.36 (0.63–2.78) 1.58 (0.78–7.29) 2.92 (1.00–7.63)
AT 1.14 (0.51–2.18) 1.41 (0.77–4.73) 2.05 (0.49–6.64)
TT 2.50 (1.18–3.00) 5.17 (0.86–18.5) 4.66 (1.50–8.11)
TNFA −1031T > C 0.74 0.42 0.71
TT 1.41 (0.60–2.97) 1.34 (0.79–5.38) 3.74 (0.96–7.57)
TC 1.49 (0.58–2.50) 1.66 (0.79–6.87) 2.60 (0.51–6.93)
CC 1.45 (1.01–1.52) 8.57 (0.73–14.89) 2.12 (1.32–2.59)
TNFA −308G > A 0.41 0.58 0.50
GG 1.67 (0.65–2.80) 1.66 (0.79–6.30) 2.92 (0.89–7.58)
GA 1.14 (0.58–2.23) 1.48 (0.73–3.42) 2.61 (1.18–6.54)
AA 0.62 (0.51–0.62) 1.39 (0.96–1.39) 1.30 (0.28–1.30)
TNFA −238G > A 0.76 0.97 0.61
GG 1.45 (0.64–2.66) 1.59 (0.81–5.59) 2.61 (0.94–7.47)
GA 1.34 (0.53–2.91) 1.48 (0.76–7.16) 5.15 (1.69–8.16)
AA 2.32 (2.32–2.32) 1.28 (1.28–1.28) 3.04 (3.04–3.04)
IL10 −819C > T 0.79 0.57 0.99
CC 1.35 (0.63‑2.53) 2.01 (0.79–5.91) 3.50 (0.55–7.48)
CT 1.45 (0.60‑2.77) 1.29 (0.77–5.06) 2.61 (0.87–7.60)
TT 2.22 (0.83–2.84) 2.18 (1.35–6.31) 1.98 (1.22–7.13)
IL10 −592C > A 0.86 0.86 0.77
CC 1.41 (0.62–2.50) 1.59 (0.76–5.91) 4.92 (1.10–7.63)
CA 1.52 (0.62–2.78) 1.46 (0.81–5.46) 2.59 (0.94–7.26)
AA 1.22 (0.52–2.85) 1.84 (1.21–4.32) 2.50 (1.07–5.97)
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been observed between the T allele of this SNP and high 
IFN-γ production [34]. The results of individuals carry-
ing the TT (Table 2) genotype had higher levels of anti-
PvAMA-1, -PvMSP-119 and -PvDBP IgG antibodies than 
those with the TA or AA genotypes, although the asso-
ciation was not significant. Thus, the TT genotype may 
not be related to increased production of IFN-γ, which 
would negatively modulate the Th2 immune response 
and antibody production in the analysed samples, given 
that these patients had higher antibody levels.
TNF participates in the total IgG response, which is 
mediated by follicular dendritic cells and dependent on 
soluble TNFR1 signalling [35], and high levels of this 
cytokine are related to malarial paroxysm [32] and severe 
malaria [6]. The A allele of TNFA (−308, −238) has been 
associated with elevated levels of antibodies in falcipa-
rum malaria [6, 35, 36]. At positions −863 and −857, the 
A and T alleles, respectively, have been associated with 
high levels of IgG3 and IgG4 antibodies in malaria [37]. In 
Tanzania, Carpenter et al. [11] reported a negative asso-
ciation between levels of anti-P. falciparum IgG antibod-
ies and the A allele (−308) in malaria patients. In a study 
of SNPs in the TNFA gene in Burkina Faso, the A (−863), 
T (−857) and G (−1304) alleles in particular were associ-
ated with total IgG levels against P. falciparum; however, 
no association was found for positions −1031, −308 or 
−238 of this gene [6]. This prevalence of subjects indi-
viduals with the A allele (TNF308G > A) had the lowest 
levels of anti-PvAMA-1, -PvMSP-119 and -PvDBP IgG 
antibodies, but the association was not significant.
Interleukin 4, IL-10 and IL-13 are anti-inflammatory 
cytokines involved in antibody production mechanisms 
[3]. IL-10 is a Th2-type immunoregulatory cytokine that 
negatively modulates the effects of pro-inflammatory 
cytokines produced by Th1 cells [29, 30, 38], partici-
pates in the induction of immunoglobulin synthesis and 
promotes isotype class switching from IgM to IgG1 and 
from IgG1 to IgG3 [6]. The AA genotype (−1082) has 
been associated with high levels of anti-MSP-2/31D7 and 
-AMA-1 IgG antibodies in mothers and newborns with 
falciparum malaria in Uganda [3]. In patients with falci-
parum malaria in Tanzania, the A allele (−592, −1082) 
was associated with low levels of IgE and IgG4 [11]. SNPs 
(−592 and −819) were associated with high levels of IgE 
and P. falciparum NANP (IgG) antigen antibodies in Sri 
Lanka [39]. Haplotypes IL10−1082/−819/−592 GCC, 
ACC and ATA were correlated with high, intermediate 
and low levels, respectively, of the IL-10 cytokine [29, 
40]. It has been hypothesized that high cytokine concen-
trations are associated with the presence of the C allele 
at positions −819 and −592 based on the observation 
that IL-10 participates in the immunological activa-
tion of antibody production. However, this proposition 
was supported for the analyses carried out only for anti-
PvMSP-119 IgG for these genotypes. The opposite 
occurred in the presence of the TT (−819) and AA 
(−592) genotypes associated with low production of anti-
MSP-119; however, there was no statistical significance in 
either case. This finding may be due to low serum con-
centrations of the cytokine resulting from other factors 
or to the non-influence of these SNPS on IL-10 levels and 
antibodies in the patients evaluated in this study.
Conclusions
This study revealed no association between genotypes 
and alleles with IgG class P. vivax anti-merozoite anti-
body levels. Studies of possible associations between 
SNPs in cytokine genes and the humoral immune 
response to malaria are still incipient, and the results are 
contradictory. However, this was the first Brazilian study 
to examine this set of SNPs (IFNG-183G > T, +874A > T; 
TNFA −238G > A, −308G > A and −1031T > C; IL10-
592C > A, −819C > T) in control cases of vivax malaria. 
Immunogenetic profile studies are needed to better 
understand the immunomodulation of P. vivax; this 
research will be essential for the development of new 
malaria vaccines and treatments.
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